{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:58:59Z","timestamp":1794013139821,"version":"4.8.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Long-acting injectable (LAI) cabotegravir\/rilpivirine (CAB\/RPV) can improve adherence among adolescents and youth with HIV (AYHIV). We evaluated LAI CAB\/RPV treatment outcomes among AYHIV.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>An observational cohort study of AYHIV &lt;25 years initiated LAI CAB\/RPV from October 2021 to June 2024 as a standard of care. Descriptive data included demographics (age, race\/ethnicity and gender\/sexual orientation), body mass index, HIV history, efficacy (CD4, HIV RNA and resistance), safety and retention in care.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Twenty-five AYHIV (48% cisgender females; median age, 19 years; 64% with perinatally acquired HIV; median body mass index = 25.3\u2009kg\/m<jats:sup>2<\/jats:sup>; 52% virally suppressed for \u22656 months) received LAI CAB\/RPV for a median duration of 11.8 (range, 0.8\u201331.3) months. Majority (n=24; 96%) initiated monthly LAI CAB\/RPV injections, and 19 AYHIV (76%) switched to bimonthly injections. Seven AYHIV (28%) experienced transient viremia episodes (1\u20135\/person; ranges, 48\u20131100 copies\/mL) with most (78%) occurring within the initial 12 months, all episodes resolved at retesting after 3 to 91 days and none resulted in CAB and\/or RPV resistance. Injection-associated pain\/discomfort was mild to moderate and decreased over time. Grade 2 adverse events were self-resolved and included 3 AYHIV with postinjection adverse reactions and 1 AYHIV with QTc prolongation. Three cisgender female AYHIV became pregnant and continued LAI CAB\/RPV. There were no discontinuations, missed or delayed injections. All AYHIV were virally suppressed at the end of the study follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>We report 100% engagement in care and viral suppression among 25 AYHIV on LAI CAB\/RPV during study follow-up. More data are needed to evaluate the long-term outcomes and sustainability of LAI CAB\/RPV treatment in AYHIV.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004742","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T16:12:21Z","timestamp":1737735141000},"page":"650-656","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy, Safety and Retention in Care Among Adolescents and Youth With HIV on Long-acting Injectable Cabotegravir\/Rilpivirine Treatment: Real-world Observational Cohort Outcomes"],"prefix":"10.1097","volume":"44","author":[{"given":"Tierra","family":"Williams","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Unternaher","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Li Adeline","family":"Koay","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorato","family":"Anderson","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases"},{"name":"Department of Pediatrics, The George Washington University School of Medicine, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Bright","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Mareuil","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases"},{"name":"Division of Hematology, Children\u2019s National Hospital, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2246-4581","authenticated-orcid":false,"given":"Natella","family":"Rakhmanina","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases"},{"name":"Department of Pediatrics, The George Washington University School of Medicine, Washington, DC"},{"name":"Technical Strategies and Innovation, Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"R1-20250613","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1177\/1049732317697674","article-title":"Qualitative comparison of barriers to antiretroviral medication adherence among perinatally and behaviorally HIV-infected youth.","volume":"27","author":"Fields","year":"2017","journal-title":"Qual Health Res"},{"key":"R2-20250613","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/apc.2021.0005","article-title":"Correlates of high HIV viral load and antiretroviral therapy adherence among viremic youth in the United States enrolled in an adherence improvement intervention.","volume":"35","author":"Amico","year":"2021","journal-title":"AIDS Patient Care STDS"},{"key":"R3-20250613","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1097\/QAD.0000000000002301","article-title":"Nonadherence and unsuppressed viral load across adolescence among US youth with perinatally acquired HIV.","volume":"33","author":"Kacanek","year":"2019","journal-title":"AIDS"},{"key":"R4-20250613","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/COH.0000000000000880","article-title":"Adolescents and young adults with HIV and unsuppressed viral load: where do we go from here?","volume":"19","author":"Rakhmanina","year":"2024","journal-title":"Curr Opin HIV AIDS"},{"key":"R5-20250613","doi-asserted-by":"crossref","first-page":"317","DOI":"10.15585\/mmwr.mm7212e1","article-title":"Progress toward eliminating HIV as a global public health threat through scale-up of antiretroviral therapy and health system strengthening supported by the U.S. President\u2019s emergency plan for AIDS relief \u2014 worldwide, 2004\u20132022.","volume":"72","author":"Chun","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R7-20250613","doi-asserted-by":"crossref","first-page":"ofac293","DOI":"10.1093\/ofid\/ofac293","article-title":"Are patients and their providers talking about long-acting injectable antiretroviral therapy? Penetration into clinical encounters at three U.S. care sites.","volume":"9","author":"Christopoulos","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"R8-20250613","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12905-020-01011-8","article-title":"Examining adherence barriers among women with HIV to tailor outreach for long-acting injectable antiretroviral therapy.","volume":"20","author":"Benning","year":"2020","journal-title":"BMC Womens Health"},{"key":"R9-20250613","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/JNC.0000000000000386","article-title":"Injectable long-acting cabotegravir\u2013rilpivirine therapy for people living with HIV\/AIDS: addressing implementation barriers from the start.","volume":"34","author":"Pinto","year":"2023","journal-title":"J Assoc Nurses AIDS Care"},{"key":"R10-20250613","doi-asserted-by":"crossref","first-page":"e0190487","DOI":"10.1371\/journal.pone.0190487","article-title":"Experiences with long acting injectable ART: a qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain.","volume":"13","author":"Kerrigan","year":"2018","journal-title":"PLoS One"},{"key":"R11-20250613","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.","volume":"390","author":"Margolis","year":"2017","journal-title":"Lancet"},{"key":"R12-20250613","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2352-3018(20)30340-4","article-title":"Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"key":"R13-20250613","doi-asserted-by":"crossref","first-page":"e679","DOI":"10.1016\/S2352-3018(21)00185-5","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.","volume":"8","author":"Jaeger","year":"2021","journal-title":"Lancet HIV"},{"key":"R14-20250613","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/QAD.0000000000003025","article-title":"Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment.","volume":"36","author":"Swindells","year":"2022","journal-title":"AIDS"},{"key":"R15-20250613","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1473-3099(24)00289-5","article-title":"Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.","volume":"24","author":"Kityo","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"R16-20250613","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/QAD.0000000000003446","article-title":"Single-center experience evaluating and initiating people with HIV on long-acting cabotegravir\/rilpivirine.","volume":"37","author":"Hill","year":"2023","journal-title":"AIDS"},{"issue":"Supplement_2","key":"R17-20250613","doi-asserted-by":"crossref","first-page":"S735","DOI":"10.1093\/ofid\/ofad500.1422","article-title":"1587. SOLAR 12-Month North American Results: Randomized Switch Trial of CAB+RPV LA vs. Oral BIC\/FTC\/TAF.","volume":"10","author":"McKellar","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"Supplement_2","key":"R18-20250613","doi-asserted-by":"crossref","first-page":"S749","DOI":"10.1093\/ofid\/ofad500.1450","article-title":"1615. Efficacy of long-acting cabotegravir and rilpivirine in a diverse group of patients in a real-world setting.","volume":"10","author":"Yared","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"Supplement_2","key":"R19-20250613","doi-asserted-by":"crossref","first-page":"S737","DOI":"10.1093\/ofid\/ofad500.1427","article-title":"1592. Real-world utilization and effectiveness of long-acting cabotegravir + rilpivirine among people with HIV with detectable viral loads at initiation: trio cohort study.","volume":"10","author":"Elion","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"Supplement_2","key":"R20-20250613","doi-asserted-by":"crossref","first-page":"S724","DOI":"10.1093\/ofid\/ofad500.1402","article-title":"1567. Perspectives of people with HIV (PWH) 6 months following a switch to cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world US study (BEYOND).","volume":"10","author":"Dandachi","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"R21-20250613","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.1016\/S2352-3018(23)00301-6","article-title":"Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017\/MOCHA): a secondary analysis of a phase 1\/2, multicentre, open-label, non-comparative dose-finding study.","volume":"11","author":"Lowenthal","year":"2024","journal-title":"Lancet HIV"},{"key":"R23-20250613","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/S2352-3018(23)00300-4","article-title":"Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017\/MOCHA): a phase 1\/2, multicentre, open-label, non-comparative, dose-finding study.","volume":"11","author":"Gaur","year":"2024","journal-title":"Lancet HIV"},{"key":"R24-20250613","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S2352-3018(24)00039-0","article-title":"Are we ready for long-acting HIV treatment for adolescents?","volume":"11","author":"Rakhmanina","year":"2024","journal-title":"Lancet HIV"},{"key":"R25-20250613"},{"key":"R26-20250613","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/jpids\/piae033","article-title":"Off-label use of long-acting injectable antiretroviral therapy: a single center retrospective review of youth living with HIV with detectable HIV RNA starting injectable therapy.","volume":"13","author":"Rousseau","year":"2024","journal-title":"J. Pediatric Infect Dis Soc"},{"key":"R27-20250613"},{"key":"R28-20250613","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1097\/QAI.0000000000003142","article-title":"Transient viremia in young adults with HIV after the switch to long-acting cabotegravir and rilpivirine: considerations for dosing schedule and monitoring.","volume":"92","author":"Rakhmanina","year":"2023","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Supplement_2","key":"R30-20250613","doi-asserted-by":"crossref","first-page":"S741","DOI":"10.1093\/ofid\/ofad500.1434","article-title":"1599. Real-world efficacy of long-acting cabotegravir and rilpivirine in an urban HIV clinic.","volume":"10","author":"Perez","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"R31-20250613","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1093\/cid\/ciac631","article-title":"First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable human immunodeficiency virus (HIV) viremia in an urban HIV clinic.","volume":"76","author":"Christopoulos","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"Supplement_2","key":"R32-20250613","doi-asserted-by":"crossref","first-page":"S745","DOI":"10.1093\/ofid\/ofad500.1442","article-title":"1607. Clinical outcomes at month 6 after initiation of cabotegravir and rilpivirine long-acting (CAB + RPV LA) in an observational real-world study (BEYOND).","volume":"10","author":"Sinclair","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"R33-20250613","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/hiv.13679","article-title":"Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI-net).","volume":"25","author":"Ring","year":"2024","journal-title":"HIV Med"},{"key":"R34-20250613","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1089\/aid.2024.0007","article-title":"Early implementation and outcomes among people with HIV who accessed long-acting injectable cabotegravir\/rilpivirine at two Ryan white clinics in the U.S. South.","volume":"40","author":"Haser","year":"2024","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R35-20250613","doi-asserted-by":"crossref","first-page":"969","DOI":"10.7326\/M23-0788","article-title":"Demonstration project of long-acting antiretroviral therapy in a diverse population of people with HIV.","volume":"176","author":"Gandhi","year":"2023","journal-title":"Ann Intern Med"},{"key":"R36-20250613","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jama.2024.2985","article-title":"Updated treatment recommendation on use of cabotegravir and rilpivirine for people with HIV from the IAS-USA guidelines panel.","volume":"331","author":"Sax","year":"2024","journal-title":"JAMA"},{"key":"R37-20250613","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/cid\/ciad511","article-title":"Long-acting injectable cabotegravir\/rilpivirine effective in a small patient cohort with virologic failure on oral antiretroviral therapy.","volume":"78","author":"Brock","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"Supplement_2","key":"R38-20250613","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1093\/ofid\/ofad500.059","article-title":"1028. Real-world use of long-acting cabotegravir + rilpivirine in people with HIV with detectable viral loads at initiation: findings from the OPERA\u00ae cohort.","volume":"10","author":"Hsu","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"R39-20250613","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/jac\/dkz141","article-title":"Concentration-response model of rilpivirine in a cohort of HIV-1-infected naive and pre-treated patients.","volume":"74","author":"Neant","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"R40-20250613","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1111\/bcp.14344","article-title":"Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV-infected patients.","volume":"86","author":"Neant","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"R41-20250613","first-page":"ciae475","article-title":"Virological history predicts non-sustained viral suppression with long-acting cabotegravir and rilpivirine therapy, independent of pharmacokinetic parameters.","author":"Guti\u00e9rrez","year":"2024","journal-title":"Clin Infect Dis"},{"key":"R42-20250613","doi-asserted-by":"crossref","first-page":"100793","DOI":"10.1016\/j.lanepe.2023.100793","article-title":"Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland.","volume":"36","author":"Thoueille","year":"2024","journal-title":"Lancet Reg Health. Eur"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004742","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T22:04:33Z","timestamp":1749852273000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004742","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]}}}